Part of Smith & Nephew plc, Smith & Nephew Orthopaedics GmbH is a company headquartered in Tuttlingen, Germany, that manufactures medical devices. Prengel Timo and Wawrzynek Ramona are the current co-CEOs of the firm.

MediWound is a biotechnology niche-specialty company. Established in 2001, MediWound is focused on developing, manufacturing, and globally commercializing innovative products that address unmet needs in the fields of severe burns and chronic wound management. MediWound’s goal is to provide healthcare professionals and patients with its innovative burn wound eschar removal agent, NexoBrid. NexoBrid successfully completed clinical development in hospitalized burn wounds and is approved and ready to launch in Europe.

Tenex Health, Inc. develops and provides minimally invasive therapies for removal of diseased soft tissue and restoration of healthy musculoskeletal function. The firm specializes in procedures that allow physicians to identify, debride, and aspirate pain-generating pathologic soft tissue in tendons and other musculoskeletal structures of the elbow, knee, ankle, foot, and shoulder. The company was founded by Jagi Gill in 2009 and is headquartered in Lake Forest, CA.

Healthpoint is a privately held company focused on the development and commercialisation of novel, cost-effective bioactive solutions for debridement, dermal repair and regeneration. Its principal marketed product is Collagenase SANTYL® Ointment (“SANTYL”), an enzymatic debrider for dermal ulcers and burns. Healthpoint’s offering also includes the OASIS® family of leading acellular skin substitutes for venous leg ulcers and diabetic foot ulcers and REGRANEX®, a growth factor for treating diabetic foot ulcers. The company’s research and development strategy is centred on next-generation bioactive therapies for the treatment of chronic wounds. The principal pipeline product is HP802-247 for the treatment of venous leg ulcers, using cell-based therapy containing keratinocytes and fibroblasts. In August 2011 Healthpoint reported positive data from a Phase 2b clinical trial for HP802-247 in the treatment of venous leg ulcers, demonstrating that the compound met both its primary and secondary endpoints. The compound has recently entered Phase 3 trials for this indication and commercial launch could occur as early as 2017.

reGenics is a private biotechnology company that develops a range of wound care products.

Hollister, Inc. develops, manufactures and markets healthcare products and services. Its products include Ostomy, continence, wound, skin and critical care products. The company was founded by John Dickinson Schneider in 1921 and is headquartered in Libertyville, IL.

General Electric Capital Corp. provides financial products and services. Its services include commercial loans and leases, fleet management, financial programs, credit cards, personal loans, and other financial services. The firm’s solutions include energy finance and aviation finance. The company was founded in 1932 and is headquartered in Boston, MA.

Hocermed is a provider of energy platforms for invasive surgery. They has established research and development bases. They creates a comprehensive system that supports research and development, quality control, production, sales, and service. They  supplies products with minimally invasive surgical solutions to healthcare professionals.  They also invasive surgical energy devices. They provides surgical products and  services to surgeons.

Develops, produces and distributes medical and hygiene products

Smith & Nephew PLC designs, manufactures and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is a sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Develops medical applications and devices

Functions as a financial holding company

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

3M Innovative Properties Co. acquires and manages intellectual property right. It engages in the acquisition and ownership of the intellectual property rights to the products designed and manufactured by its parent company 3M Corporation. The company was founded on May 10, 1999 and is headquartered in Roseville, MN.

Alliqua is a biomedical company focused on the development, manufacturing, and marketing of its own proprietary products, utilizing its existing technology portfolio. The company currently markets its own proprietary brands of wound dressings such as SilverSeal® Hydrogel, an antimicrobial dressing; and Hydress® a moist wound dressing. The company intends to pursue projects in the fields of the active ingredient and transdermal drug delivery, as well as advanced wound care. Alliqua’s core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin.

Wuhan Center Hospital is a Chinese private company located in Wuhan that engages in providing general medical and surgical services and other hospital services.

Tianjin Kaiyin Technology Co., Ltd., established on 2015-03-09, Business scope includes biomedical technology,chemical product,Technology development of medical devices,technical consulting,Technical Services,technology transfer;On-site maintenance and installation of laboratory equipment;Chemical Products and Raw Materials,Sales of laboratory equipment and accessories;Self-operated and agent goods and technology import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.